Sarepta Therapeutics Inc: This Chart Shows Where SRPT Stock Could Go Next

Sarepta Therapeutics IncSRPT Stock: Not for the Faint of Heart

Sarepta Therapeutics Inc (NASDAQ:SRPT) stock has had a difficult year gaining traction.

Year-to-date, SRPT stock is down 36%, but that’s not the whole story. At 9:30 a.m. on April 26, SRPT stock was registering a loss of 79% year-to-date. That is a painful loss to digest and this investment can best be described as a weapon of wealth destruction. The cause of all this volatility stems from negative news that has been surrounding a breakthrough drug Sarepta is seeking Food & Drug Administration (FDA) approval on.

The drug in question is called “Eteplirsen” and it treats Duchenne muscular dystrophy (DMD). The weight placed on this one drug is so heavy it is causing wild and erratic swings in SRPT stock.

Looking at the chart below, you can see the gaps in the share price caused by the news surrounding this drug:

Sarepta Therapeutics Inc NASDAQ Chart

Chart courtesy of www.

The following news-driven events caused the share price volatility:

  1. January 15, 2016: The FDA released a negative report regarding Sarepta’s DMD drug. SRPT stock gapped down and closed down 55%.
  2. April 21, 2016: The FDA reviewed the original report at the company’s request and the same conclusion was reached. SRPT stock gapped down and closed down 44%.
  3. April 26, 2016: Sarepta disclosed that the FDA denied accelerated approval of Sarepta’s DMD drug. SRPT stock gapped down and closed down 26%.
  4. April 28, 2016: Rumors spread that there were still possibilities of early drug approval. SRPT stock gapped up and closed up 19.5%.
  5. May 25, 2016: The FDA delayed a ruling on Sarepta’s DMD drug. The delay raised hopes of a possible approval. SRPT stock gapped up and closed up 26.6%.
  6. June 2, 2016: Rumors swirled that the FDA could force Sarepta to provide the DMD drug at cost to patients. SRPT stock gapped down and closed down 26.6%.
  7. June 7, 2016: The FDA requested more data on the DMD drug and Sarepta got upgraded by Wedbush Securities. SRPT stock gapped up and closed up 22.6%.

It is incredible to imagine, but we can expect minimum moves of 20% in share price based on any news surrounding the drug. Who can sleep at night knowing they can wake up the next morning to such volatility? SRPT stock is not for the faint of heart.

Perhaps the chart below can shed some light and help investors gain a foothold. The SRPT stock chart below contains year-to-date data.

Sarepta Therapeutics Inc NASDAQ INDX

Chart courtesy of www.

SRPT stock is currently bumping up against resistance. Every time the bulls try and challenge this price point, the bears come in and overwhelm the bulls with selling pressure. The good news for the bulls is that resistance can be overcome. The blue line represents a battle line; if the price can close above $25.00, it is suggesting a win for the bull camp. A win for the bulls would probably coincide with a positive FDA ruling.

The Bottom Line on SRPT Stock

As an investor, I would stay away from such an investment as Sarepta; the emotional toll alone is reason enough to stand aside. Daily swings of 20% are becoming the norm and are likely to cause anyone some sleepless nights. If you are willing to take the risk, a close above $25.00 would be a positive sign regarding FDA approval and could provide windfall profits for SRPT stock investors.